Tg Therapeutics (TGTX) Receivables (2010 - 2026)
Tg Therapeutics (TGTX) posted quarterly Receivables of $392.0 million for Q1 2026, up 2825.72% year-over-year from $13.4 million in Q1 2025, and up 28.28% quarter-over-quarter from $305.6 million in Q4 2025.
Tg Therapeutics (TGTX) Receivables (2010 - 2026) Analysis & Trends
Tg Therapeutics' Receivables history runs 8 years deep, the most recent figure standing at $392.0 million for Q1 2026.
- In Q1 2026, Receivables rose 2825.72% year-over-year to $392.0 million; the TTM figure through Mar 2026 stood at $392.0 million (up 2825.72% YoY), while the FY2025 annual figure was $305.6 million, up 136.58% from the prior year.
- Receivables for Q1 2026 stood at $392.0 million, up from $305.6 million in the prior quarter.
- The five-year high for Receivables was $392.0 million in Q1 2026, with the low at $88000.0 in Q2 2022.
- The 5-year median for Receivables is $65.0 million (2024), against an average of $114.6 million.
- The sharpest annual moves came in 2022 and 2023: Receivables sank 90.55% in 2022, then soared 19768.18% in 2023.
- Tg Therapeutics' Receivables stood at $88000.0 in 2022, then surged by 57960.23% to $51.1 million in 2023, then soared by 152.84% to $129.2 million in 2024, then soared by 136.58% to $305.6 million in 2025, then rose by 28.28% to $392.0 million in 2026.
- Business Quant data shows TGTX's Receivables at $392.0 million in Q1 2026, $305.6 million in Q4 2025, and $265.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.13 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 6.57 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.93 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.06 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1.84 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 912.74 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 215.33 Mn |
| 10 | Tg Therapeutics | 7.46 Bn | 6.78 Bn | 199.14 Mn | 401.57 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 401.57 Mn |
| Mar 31, 2026 | 392.05 Mn |
| Dec 31, 2025 | 305.63 Mn |
| Sep 30, 2025 | 265.38 Mn |
| Jun 30, 2025 | 231.52 Mn |
| Mar 31, 2025 | 13.40 Mn |
| Dec 31, 2024 | 129.19 Mn |
| Sep 30, 2024 | 115.73 Mn |
| Jun 30, 2024 | 83.61 Mn |
| Mar 31, 2024 | 64.98 Mn |
| Dec 31, 2023 | 51.09 Mn |
| Sep 30, 2023 | 39.32 Mn |
| Jun 30, 2023 | 17.48 Mn |
| Mar 31, 2023 | 8.62 Mn |
| Jun 30, 2022 | 88,000.00 |
| Mar 31, 2022 | 903,000.00 |
| Dec 31, 2021 | 1.39 Mn |
| Sep 30, 2021 | 1.38 Mn |
| Jun 30, 2021 | 931,000.00 |
| Mar 31, 2021 | 771,000.00 |